ClinicalTrials.gov record
Completed Phase 1 Interventional

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

ClinicalTrials.gov ID: NCT04823702

Public ClinicalTrials.gov record NCT04823702. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Aldafermin in Subjects With Impaired Hepatic Function

Study identification

NCT ID
NCT04823702
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Enrollment
36 participants

Conditions and interventions

Interventions

  • Aldafermin Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2021
Primary completion
Nov 18, 2021
Completion
Nov 18, 2021
Last update posted
Jan 18, 2022

2021

United States locations

U.S. sites
3
U.S. states
2
U.S. cities
3
Facility City State ZIP Site status
NGM Clinical Study Site 110 Miami Florida 33014
NGM Clinical Study Site 111 Orlando Florida 32809
NGM Clinical Study Site 113 San Antonio Texas 78215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04823702, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 18, 2022 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04823702 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →